The Triad Of PCOS, Infertility And Metformin
DOI:
https://doi.org/10.51985/JBUMDC2018144Keywords:
Polycystic ovarian syndrome, Reproductive abnormalities, Obesity, Insulin resistance, Infertility, MetforminAbstract
Polycystic ovarian syndrome (PCOS) is now considered as a complicated disease of endocrine system. It is found in 5-
10% of women of fertile age group. It was initially considered as a reproductive disorder in women. Studies in recent past
have documented that PCOS is a metabolic syndrome and is influenced by genetic and environmental factors. It is also
transferred genetically, an autosomal dominant trait with variable penetrance. Since role of insulin resistance has been
identified as a main culprit in the development of PCOS therefore use of insulin sensitizers to treat PCOS seems logical.
Insulin sensitizer such as metformin is a therapeutic option that targets not only insulin resistance present in this syndrome
but several other aspects especially reproductive abnormalities such as infertility, which is a major problem of concern for
women of reproductive age. This review attempts to cover the use of metformin in PCOS infertile women.
References
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841-55.
Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84.
Kim JY, Tfayli H, Michaliszyn SF. Distinguishing characteristics of metabolically healthy versus metabolically unhealthy obese adolescent girls with polycystic ovary syndrome. FertilSteril. 2016; 105:1603-11.
Rosenfield RL. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics. 2015; 136:1154–65.
Kosova G, Uebanek M. Genetics of the polycystic ovary syndrome. Mol Cell Endocrinol. 2013; 373:29-38.
McCartney CR, Marshall JC. Polycystic ovary syndrome. N Engl J Med. 2016; 375:54-64.
De Leo V, Musacchio MC, Cappelli V. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016; 14:38.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. FertilSteril. 2004; 81(1):19-25.
Manmohan K. Kamboj, Andrea E. Bonny. Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies 2017; 6(4): 248–255. doi:10.21037/tp.2017.09.11.
Ibanez L, Ong KK, Lopez-Bermejo A. Hyperinsulinaemic androgen excess in adolescent girls. Nat Rev Endocrinol. 2014;10 (8):499-508.
Marsh CA, Grimstad FW. Primary amenorrhea: diagnosis and management. Obstet Gynecol Surv. 2014;69:603-12.
Witchel SF, Oberfield S, Rosenfield RL. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr. 2015;87:376-89.
Glueck CJ,Woo JG, Khoury PR, Morrison JA, Daniels SR, Wang P. Adolescent oligomenorrhea (age 14–19) tracks into the third decade of life (age 20–28) and predicts increased cardiovascular risk factors and metabolic syndrome. Metabolism. 2015;64:539- 53.
Shen Y, Wang T, Zhou C. Prevalence of acne vulgaris in Chinese adolescents and adults: A community-based study of 17,345 subjects in six cities. Acta Derm. Venereol. 2012; 92: 40-4.
Eichenfield LF, Krakowski AC, Piggott C. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013; 131 (Suppl. 3): S163–86.
Roe AH, Prochaska E, Smith M. Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. J Pediatr. 2013;162(5):937-41.
Maliqueo M, Lara HE, Sanchez F. Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur J ObstetGynecolReprodBiol. 2013;166:151-5.
Jose Bellver et al;Polycystic ovary syndrome throughout a woman’s life.J Assist Reprod Genet. 2018; 35:25-39. doi: 10.1007/s10815-017-1047-7
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome 1093 revisited: an update on mechanisms and implications. Endocrine Reviews 2012; 33: 981-1094. doi: 10.1210/er.2011-1034.
Barbosa-Desongles A, Hernández C, Simo R,Selva DM. Testosterone induces cell proliferation and cell cycle gene overexpression in humanvisceralpreadipocytes. Am J Physiol Cell Physiol. 2013; 305: C355-59.
Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014; 20:334-52.
Balen AH, Morley LC, Misso M. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016; 22:687–708.
Mendoza N, Simoncini T, Genazzani AD. Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies. Gynecol Endocrinol. 2014;25:1–11.
Hu L, Shen H, Wu QF. Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. Clin Exp Obstet Gynecol. 2014;41:288-92.
Panidis D, Tyiomalos K, Papadakis E, Katsikis I. Infertility treatment in polycystic ovary syndrome: lifestyle interventions, medications and surgery. Front Horm Res. 2013; 40: 128-141.
Hashim H A. Twenty years of ovulation induction withmetformin for PCOS; what is the best available evidence? Reproductive BioMedicine Online.2016; 32: 44-53.
Sirmans SM, Pate KA. Epidemiology, diagnosis and management of polycystic ovary syndrome.Clin Epidemiol. 2014; 6:1-13. doi:10.2147/CLEP.S37559.
Day FR, Hinds DA, Tung JY, et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat Commun. 2015;6:8464.
Connolly A, Beckett V. Polycystic ovary syndrome—management of a long-term condition in primary care. In: Connolly A, Britton A, editors. Women’s health in primary care. Cambridge: Cambridge University Press, 2017: 111-18.
Jayasena, C N, Franks S. The management of patients with polycystic ovary syndrome. Nature Reviews Endocrinology, 2014;10 (10), 624-36. doi:10.1038/nrendo.2014.102
Homburg R, Ray A, Bhide P. The relationship of serum anti-Mullerian hormone and polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Human Reprod. 2013; 28:1077-83.
Panidis D, Tziomalos K, Papadakis E. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.Endocrine. 2013;44:583-90.
Sanchez-Rangel, E. Inzucchi SE. Metformin: Clinical use in type2 diabetes. Diabetologia. 2017; 60:1586-93.
Sivalingam VN, Myers J, Nicholas S, Balen AH, Crosbie EJ. Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. Hum Reprod Update. 2014;20:853-68.
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitizing drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017 Nov 29;11: CD003053.
Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev.2014 ;11: CD006105.
Cassina M, Dona M, Di Gianantonio E. First-trimester exposure to metformin and risk of birth defects: a systematic review and metaanalysis. Hum Reprod Update. 2014; 20:656-69.
Li Gong, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 ; 22(11): 820-27. doi:10.1097/FPC.0b013e3283559b22.
Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56:1898-906.
Naderpoor N, Shorakae S, Courten B, Misso M L, Moran L J, Teede H J. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Human Reproduction Update. 2015; 21(5): 560-74. doi:10.1093/humupd/dmv025.
Pasquali R.Contemporary approaches to the management of polycystic ovary syndrome. Ther Adv EndocrinolMetab. 2018;9 (4)123-34. doi: 10.1177/2042018818756790.
Elizabeth Sanchez-Rangel1, Silvio E, Inzucchi. Metformin: clinical use in type 2 diabetes Diabetologia. 2017;60:1586 -93 doi:10.1007/s00125-017-4336-x.
DeFronzo R, Fleming GA, Chen K, Bicsak TA.Metformin associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016; 65:20-29.
Aroda VR, Edelstein SL, Goldberg RB. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101:1754 -61.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Ayesha Khan, Nasim Karim, Jahan Ara Ainuddin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
